NeuBase Therapeutics, Inc. (NBSE) Social Stream
NeuBase Therapeutics Inc (NBSE) Price Targets From Analysts
Use the tables below to see what analysts covering NeuBase Therapeutics Inc think about its future price and what recommendations they have for investors and traders.
|Date||Number of Analysts||Highest Target Price||Lowest Target Price||Average Target Price||Current Price||Upside Potential|
The Trend in the Analyst Price Target
NBSE's average price target has moved down $0.33 over the prior 48 weeks.
Over the past 46 weeks, NBSE's average upside potential has been 317.57%.
|Date||Number of Analysts||Highest Target Price||Lowest Target Price||Average Target Price||Share Price||Upside Potential|
NBSE Broker Recommendations Summary
|Average Broker Rating||Strong Buy||Buy||Hold||Sell||Strong Sell||Analysts Issuing Recs|
The Trend in the Broker Recommendations
NBSE's average broker recommendation rating improved by 0.75 over the prior 123 days.
The bullet points below may help you gain a better understanding of what the metrics in the price target and recommendations tables above mean for NBSE as an investment opportunity.
- NBSE has a higher upside potential (average analyst target price relative to current price) than 294.69% of all US stocks.
- In the context of all US stocks, NeuBase Therapeutics Inc's number of analysts covering the stock is higher than 15.78% of them.
- In terms of how NeuBase Therapeutics Inc fares relative to Pharmaceutical Products stocks, note that its variance in analysts' estimates is lower than 60.49% of that group.
- NeuBase Therapeutics Inc's average analyst price target is higher than 82.29% of Healthcare stocks.
What is the outlook for NBSE? Use POWR Ratings for clearer insight into price direction.